Differences in preventing new‐onset cardiovascular events with statin therapy in seniors aged 75 years and over: A cohort study in the South Korean National Health Insurance Database-Reference-Cited by-同舟云学术

Differences in preventing new‐onset cardiovascular events with statin therapy in seniors aged 75 years and over: A cohort study in the South Korean National Health Insurance Database

Published:2019-04-15 Issue: Volume: Page:
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharmacol Toxicol

Author:

Kim Kyungim¹²,Kwak Arim¹,Choi Cheol Ung³,Kim Jae Hyun⁴,Kim Myeong Gyu⁵,Oh Jung Mi⁴,Ji Eunhee⁶

Affiliation:

1. College of Pharmacy Korea University Sejong South Korea

2. Biomedical Research Center Korea University Guro Hospital Seoul South Korea

3. Cardiovascular Center Korea University Guro Hospital Seoul Korea

4. College of Pharmacy and Research Institute of Pharmaceutical Sciences Seoul National University Seoul South Korea

5. Graduate School of Clinical Pharmacy CHA University Pocheon South Korea

6. College of Pharmacy Gachon University Incheon South Korea

Funder

National Research Foundation

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcpt.13229

Reference29 articles.

1. Wan HeDG KowalP.International Population Reports P95/16‐1 An Aging World: 2015. In:BureauUed.Washington DC:U.S. Government Publishing Office;2016.

2. National Heart Lung and Blood Institute. Morbidity and mortality: 2012 chart book on cardiovascular lung and blood diseases: National Institute of Health;2012.https://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdf.

3. Cholesterol lowering in intermediate‐risk persons without cardiovascular disease;Yusuf S;N Engl J Med.,2016

4. Rosuvastatin for primary prevention among individuals with elevated high‐sensitivity c‐reactive protein and 5% to 10% and 10% to 20% 10‐year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk";Ridker PM;Circ Cardiovasc Qual Outcomes.,2010

5. Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C‐reactive protein and low to average low‐density lipoprotein cholesterol levels: exploratory analysis of a randomized trial;Glynn RJ;Ann Intern Med.,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review;BMC Medical Research Methodology;2021-11-06

2. Statin therapy for primary cardiovascular prevention in adults older than 75 years;Kardiologia Polska;2021-01-25